Search Results - "Nakhoda, Shazia K."

COVID-19 Vaccine–Related Local FDG Uptake by Doss, Mohan, Nakhoda, Shazia K., Li, Yi, Yu, Jian Q.

“…We present a case of increased FDG uptake in the lymph nodes after COVID-19 vaccine administration. Restaging PET/CT scan of a 70-year-old woman with a history…”
Get full text

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial by Budde, Lihua E., Olszewski, Adam J., Assouline, Sarit, Lossos, Izidore S., Diefenbach, Catherine, Kamdar, Manali, Ghosh, Nilanjan, Modi, Dipenkumar, Sabry, Waleed, Naik, Seema, Mehta, Amitkumar, Nakhoda, Shazia K., Smith, Stephen D., Dorritie, Kathleen, Jia, Ting, Pham, Song, Huw, Ling-Yuh, Jing, Jing, Wu, Hao, Ead, Wahib S., To, Iris, Batlevi, Connie Lee, Wei, Michael C., Chavez, Julio C.

“…Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet need. Here we report the primary analysis of a phase 1b/2 trial of…”
Get full text

YIA24-002: Patients' Perspectives on Being Treated by Multiple Care Teams for Autologous Transplant/CAR-T Eligible Lymphoma and Multiple Myeloma by Frosch, Zachary A K, Meshack, Clark, Meeker, Caitlin, Varshavsky-Yanovsky, Asya, Khanal, Rashmi, Bromberg, Michael, Chandar, Ashwin, Quien, Emmanuel, Carter, Jordan, Nakhoda, Shazia K, Messmer, Marcus, Montgomery, Charissa, Incorvati, Jason A, Ali, Nadia D, Styler, Michael J, Fang, Carolyn Y

Get more information

Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies by Nakhoda, Shazia K., Olszanski, Anthony J.

“…The incorporation of checkpoint inhibitors into the treatment armamentarium of oncologic therapeutics has revolutionized the course of disease in many cancers…”
Get full text

COVID-19 Vaccine–Related Local FDG Uptake by Doss, Mohan, Nakhoda, Shazia K., Li, Yi, Yu, Jian Q.

Get full text

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study by Wang, Michael L., Assouline, Sarit, Kamdar, Manali, Ghosh, Nilanjan, Naik, Seema, Nakhoda, Shazia K., Chavez, Julio C., Jia, Ting, Pham, Song, Huw, Ling-Yuh, Jing, Jing, Ead, Wahib, To, Iris, Batlevi, Connie Lee, Wei, Michael C., Budde, L. Elizabeth

“…Background: New treatment options are needed for patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL), especially for pts with progressive…”
Get full text

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study by Budde, L. Elizabeth, Olszewski, Adam J, Assouline, Sarit, Lossos, Izidore S., Diefenbach, Catherine, Kamdar, Manali, Ghosh, Nilanjan, Modi, Dipenkumar, Sabry, Waleed, Naik, Seema, Mehta, Amitkumar, Nakhoda, Shazia K., Smith, Stephen D, Dorritie, Kathleen, Jia, Ting, Pham, Song, Huw, Ling-Yuh, Wu, Hao, To, Iris, Wei, Michael C., Chavez, Julio C.

“…Background: Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody that engages and redirects T cells to eliminate malignant B cells. The…”
Get full text